Civilization Ventures

Oxford Cancer Analytics is helping physicians make better decisions through evidence based diagnostics based on combining modern machine learning AI with reproducible, high throughput measurements of the circulating proteome.

Omada Health is a virtual care program that helps individuals manage chronic conditions and achieve their health goals through personalized health programs.

BillionToOne is a molecular diagnostics company focused on creating accessible prenatal screening and liquid biopsy tests.

Foresight Diagnostics develops and delivers innovative diagnostic tests that combine precision genomics and cutting-edge bioinformatics to advance cancer drug development and patient care.

Fluent BioSciences is a life science tools company that specializes in single-cell technology, particularly for RNA sequencing. Their PIPseeker software and PIPseq technology allow for efficient single-cell analysis without the need for complex instrumentation.

Excision BioTherapeutics is a biotechnology company developing CRISPR-based therapies for viral diseases, including HIV, HSV, and HBV. It uses gene editing to excise viral DNA.

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect's bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body.

Glyphic Biotechnologies, Inc. is developing the first truly de novo high-throughput proteome sequencing technology capable of discriminating all 20 AAs and PTMs accurately with single molecule sensitivity.

Range is an all-in-one AI WealthTech platform that provides modern financial advice for investing, taxes, and comprehensive wealth management solutions. By leveraging proprietary artificial intelligence technology, Range aims to democratize access to sophisticated financial planning, making it affordable and accessible for everyone.

Teiko simplifies cytometry for global clinical trials with innovative products like blood preservation kits and multiparameter flow cytometry services.

Writes first institutional checks ($500k–$5M) at earliest stages for compute-applied chemistry and biology ventures (therapeutics, industrial biotech, climate, materials), led by an advanced-degree scientific team.

F-Prime Capital is one of the few large global VC firms that has built over 30 companies from scratch rather than just backing existing startups, drawing on Fidelity's resources to combine deep healthcare and technology expertise with a structured company-formation engine that pulls together academic founders across multiple geographies. The firm operates with sister fund Eight Roads to create one of the broadest cross-border VC footprints, systematically syndicating ideas across the U.S., Europe, China, Japan, India, and Israel while maintaining a distinctive "technical-risk-yes, regulatory-risk-no" filter that avoids heavy regulatory categories like broad antibiotics in favor of rare diseases and gene therapy where FDA pathways are clearer.

Founded by Bryan Johnson, invests in platforms and enabling technologies supporting inventors and scientists building programmable-biology solutions to rewrite life's operating systems and benefit humanity. OS Fund believes biology is programmable, and invests in platforms and enabling technologies (i.e. Ginkgo Bioworks).

A Middletown, Delaware–based firm specializing in early-stage biotech and life sciences.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.